Anne Beaven

Anne Beaven, MD, is a UNC Lineberger Comprehensive Cancer Center member, an Associate Professor, and Director of the Lymphoma Program. Beaven's research primary focuses on therapies in patients with lymphoma.

Anne Beaven

MD
Director, Lymphoma Program
UNC-Chapel Hill
Division of Hematology/Oncology 

170 Manning Dr
Campus Box 7305
Chapel Hill, NC 27599
(919) 966-9268


Area of interest

Dr. Beaven’s research focuses on investigating novel therapies in patients with lymphoma. She has a broad background in clinical care of the lymphoma patient, which allows her to better understand the needs and clinical issues of this population; a skill set that is imperative when safely conducting clinical research. She received extensive training in clinical research first as a K30 fellow in the clinical research curriculum at UNC Hospital during her oncology fellowship and later as a fellow in the Duke Department of Medicine Faculty Development Academy in Clinical/Health Services Research.

She has utilized this knowledge in the development of multiple investigator initiated trials of novel epigenetic modulating agents in lymphoma, several of which have already been published and three other manuscripts are in development. As she moves forward, the focus of her research will be three fold. First, in collaboration with Gianpietro Dotti, MD and Barbara Savoldo, MD, PhD, she will work on the development of CarT trials using novel targets in patients with Hodgkin and non-Hodgkin lymphoma, with a focus on T cell lymphoma. Her interest in T cell lymphoma will also focus on cutaneous T cell lymphomas. At UNC, she has started a multi-disciplinary Cutaneous T cell Lymphoma program, in conjunction with UNC dermatologist, Edith Bowers, M.D. As part of this program, she will develop a clinical trial program for this underserved patient population. Lastly, she has an interest in management of cancers in the elderly population and is currently developing a cooperative group clinical trial about treatment of diffuse large b cell lymphoma in patients above 80 years old. She has the research experience, the laboratory support and the clinical knowledge to successfully reach these goals.

Awards and Honors

  • Howard Hughes Grant to fund summer research in Chemistry, Wesleyan University, 1992 
  • American Society of Hematology member, 2004-present 
  • Fellowship in Hematology/Oncology NIH T32 HL007149 (Beverly Mitchell, PI), UNC-Chapel Hill, 2004-2006
  • Fellow, Clinical Research Curriculum NIH K30 HL04127 (David Ransohoff, PI), UNC-Chapel Hill, 2005-2007
  • American Society of Clinical Oncology member, 2005-present
  • T Cell Lymphoma Consortium member, 2010-present 
  • Department of Medicine Faculty Development Academy in Clinical/Health Services Research, Duke University Fellow, 2011-2013
  • ASH Advocacy Leadership Institute, Washington DC Participant, October 2014 
  • Lymphoma Research Foundation’s Mantle Cell Consortium member, 2014-present 
  • Alliance Lymphoma Leadership Committee member, 2016-present 

 

Find publications on PubMed 

Reach NC profile